Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 6/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9983955 | 0.86 | MEN1 (0.45) | ALDH1A1XBP1HTTMEN1KMT2A | |
| SCHEMBL2212463 | 0.83 | XIAP (0.45) | ALDH1A1XBP1HTTMEN1KMT2A | |
| SCHEMBL2212678 | 0.83 | XIAP (0.45) | ALDH1A1XBP1HTTMEN1KMT2A | |
| SCHEMBL2212677 | 0.83 | XIAP (0.45) | ALDH1A1XBP1HTTMEN1KMT2A | |
| SCHEMBL2210909 | 0.76 | MEN1 (0.43) | ALDH1A1XBP1HTTMEN1KMT2A | |
| SCHEMBL2210912 | 0.76 | MEN1 (0.43) | ALDH1A1XBP1HTTMEN1KMT2A | |
| SCHEMBL2210906 | 0.76 | MEN1 (0.43) | ALDH1A1XBP1HTTMEN1KMT2A | |
| SCHEMBL9983036 | 0.75 | PPARD (0.36) | ELANECMA1 | |
| SCHEMBL2208708 | 0.74 | XIAP (0.44) | ALDH1A1XBP1HTTMEN1KMT2A | |
| SCHEMBL2208710 | 0.74 | XIAP (0.44) | ALDH1A1XBP1HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | ALDH1A1 3484/4885XBP1 211/4885HTT 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.